Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.

Brittany L MurphyMin YiBanu K ArunAngelica M Gutierrez BarreraIsabelle Bedrosian

Published in: Annals of surgical oncology (2020)

In breast cancer patients who undergo multigene panel testing, a sizeable number of women with pathogenic non-BRCA germline findings are opting for CRRM. Given that the risk of contralateral breast cancer in women with most pathogenic mutations other than BRCA1/2 remains poorly characterized, these data have implications for risk counseling and for ascertaining the true risks of contralateral breast cancer in this population.

Keyphrases

breast cancer risk
machine learning
dna repair
big data
hepatitis c virus
deep learning
climate change
dna damage